Efficacy and safety of ocrelizumab is maintained in patients with RRMS with suboptimal response to prior disease-modifying therapies: 4-year NEDA data from CASTING-LIBERTO

被引：0

作者：

Oreja-Guevara, C. ^{[1
]}

Benedict, R. H. ^{[2
]}

Comi, G. ^{[3
]}

Cutter, G. ^{[4
]}

Kister, I. ^{[5
]}

Siva, A. ^{[6
]}

Wiendl, H. ^{[7
]}

Van Wijmeersch, B. ^{[8
]}

Wuerfel, J. ^{[9
,10
]}

El Azzouzi, B. ^{[11
]}

Buffels, R. ^{[11
]}

Dirks, P. ^{[11
]}

Kuenzel, T. ^{[11
]}

Vermersch, P. ^{[12
]}

机构：

[1] Hosp Clin San Carlos, Madrid, Spain

[2] SUNY Buffalo, Dept Neurol, Jacobs Sch Med & Biomed Sci, Buffalo, NY USA

[3] Univ Vita Salute San Raffaele, Milan, Italy

[4] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL USA

[5] NYU, Langone Med Ctr, Multiple Sclerosis Comprehens Care Ctr, New York, NY USA

[6] Istanbul Univ, Cerrahpasa Med Sch, Istanbul, Turkey

[7] Univ Munster, Dept Neurol, Inst Translat Neurol, Munster, Germany

[8] Hasselt Univ, Univ MS Ctr, Hasselt, Belgium

[9] Univ Basel, Dept Biomed Engn, Med Image Anal Ctr MIAC AG, Basel, Switzerland

[10] Univ Magdeburg, Dept Neuroradiol, Magdeburg, Germany

[11] F Hoffmann La Roche Ltd, Basel, Switzerland

[12] Univ Lille, Inserm LilNCog U1172, CHU Lille, FHU Precise, Lille, France

来源：

MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 3_SUPPL期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P289

引用

页码：327 / 329

页数：3

共 35 条

[31] A COST-EFFECTIVENESS ANALYSIS USING REAL-WORLD DATA FROM THE MSBASE REGISTRY: COMPARING NATALIZUMAB TO FINGOLIMOD IN PATIENTS WITH INADEQUATE RESPONSE TO DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN
Herring, W.
Gould, I. G.
Ruiz, L.
Dort, T.
Zhang, Y.
Acosta, C.
Hyde, R.
Spelman, T.
Butzkueven, H.
VALUE IN HEALTH, 2018, 21 : S338 - S338
[32] EFFICACY AND SAFETY OF UPADACITINIB VERSUS ABATACEPT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-CHOICE): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL
Rubbert-Roth, A.
Enejosa, J.
Pangan, A.
Xavier, R.
Haraoui, B.
Rischmueller, M.
Khan, N.
Zhang, Y.
Martin, N.
Genovese, M. C.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1011 - 1012
[33] Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients)
Hochhaus, Andreas
Hughes, Timothy P.
Saglio, Giuseppe
Guilhot, Francois
Al-Ali, Haifa Kathrin
Rosti, Giantonio
Nakaseko, Chiaki
De Souza, Carmino Antonio
Kemp, Charisse
Fan, Xiaolin
Hoenekopp, Albert
Larson, Richard A.
Kantarjian, Hagop M.
BLOOD, 2012, 120 (21)
[34] Letter to the Editor: In response to PR Clemens et al., Efficacy and Safety of Viltolarsen in Boys with Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study, and Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy
Muntoni, Francesco
Straub, Volker
Servais, Laurent
Mercuri, Eugenio
JOURNAL OF NEUROMUSCULAR DISEASES, 2023, 10 (06) : 1151 - 1153
[35] Reply to F. Muntoni et al.: "In response to PR Clemens et al., Efficacy and Safety of Viltolarsen in Boys with Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study, and Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy
Clemens, Paula R.
Hoffman, Eric P.
JOURNAL OF NEUROMUSCULAR DISEASES, 2023, 10 (06) : 1155 - 1157

← 1 2 3 4 →